|
|
LISTEN NOW: OUR LATEST PODCAST EPISODES |
|
|
|
| Check out the latest episodes from Cell & Gene: The Podcast and Business of Biotech. As a member of the Life Science Connect community, you have access to content beyond our weekly newsletters, including our podcast series. |
|
|
VOICES FROM THE FRONT LINE OF CELL AND GENE DISCOVERY |
|
|
|
|
| A New Approach To Genome Engineering With Tessera Therapeutics' Dr. Michael Severino | Tessera Therapeutics' CEO, Dr. Michael Severino, joins Host Erin Harris to discuss Gene Writing, the biotech's genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. Severino discusses why delivery has always been a challenge for gene editing technologies and why Gene Writing is different when it comes to efficient delivery. |
|
|
|
THE PODCAST FOR LEADERS OF EMERGING BIOPHARMA |
|
|
|
|
| Pivoting To RNA With Circio's Dr. Erik Digman Wiklund | It’s another “Business of Biotech-meets-Business-of-RNA” takeover with Circio CEO, Erik Digman Wiklund, Ph.D., and guest co-host Anna Rose Welch of Advancing RNA. While Circio’s legacy is in cancer immunology, the company made a bold pivot, of sorts, when it committed headlong to the circular RNA future. Listen in as Dr. Digman Wiklund shares insights into the challenges his company overcame to enable such a dramatic shift in focus. |
|
|
| Embracing Biotech Chaos With Memo's Erik van den Berg | Erik van den Berg is CEO and board member at Memo Therapeutics, and he's a student of biotech chaos. In fact, he's been embracing it with intention for the past 30 years. On this episode, he walks us through the management of that chaos in specific detail. |
|
|
| Picking Biotech Jockeys With SR One's Simeon George, M.D. | SR One Capital Management CEO Simeon George, M.D. has a seemingly innate ability to pick winning biotech builders. Here, Dr. George shares insight into the decision-making processes that have contributed to his success at picking winners as an investment banker and biotech venture capitalist. |
|
|
| An AI Awakening With Profluent Bio's Hilary Eaton, Ph.D. | Hilary Eaton, Ph.D. was a self-described AI skeptic, particularly regarding using the tool in drug discovery. Then, a series of professional and deeply personal life events and medical discoveries put her in a position to confront that skepticism head-on. The Chief Business Officer at ProFluent Bio shares her story and makes a pragmatic case for the transformative value of AI to biotech builders. |
|
|
